Device is a combination product.Device evaluated by mfr.: the device was not returned for analysis.The manufacturing batch record review confirmed that the device met all material, assembly and performance specifications.The investigation conclusion is anticipated procedural complication as the event is due to a known physiological effect of the procedure noted within the directions for use, and/or device labeling.(b)(4).
|
(b)(6) clinical study.It was reported that in-stent restenosis and angina occurred.In (b)(6) 2013, the patient presented with angina and st elevated myocardial infarction.Subsequently, index procedure was performed one day later.The target lesion was a de novo lesion located in the mid left anterior descending artery with 75% stenosis and was 36 mm long with a reference vessel diameter of 2.5 mm.The lesion was treated with pre-dilatation and placement of a 2.50 x 38 mm promus element¿ plus stent.Following post dilatation, residual stenosis was 0 %.On the following day, patient was discharged on aspirin and ticagrelor.In (b)(6) 2018, the patient came for a follow-up visit with the chief complaint of worsening chest pain since last month.The patient's chest pain lasted for 5 -10 minutes with nitroglycerin, however was worst with stress and exertion.The patient's chest pain with an accelerating pattern, concerned for canadian class 4 angina and the patient was scheduled for left heart catheterization in three days.In (b)(6) 2018, the patient was sent for left heart catheterization which revealed in-stent restenosis (isr) in the 60%-70% range proximally and 30% stenosis in the distal aspect of the stent.The 60-70% isr was treated with balloon angioplasty with 10% residual stenosis and timi 3 flow.On the following day, the event was considered resolved and the patient was discharged on aspirin and clopidogrel.
|